NF1 and neurofibromatosis type 1: Selumetinib has been shown to reduce p-ERK in patient PBMCs and paired tumor biopsies, but these pharmacodynamic analyses have not been conducted in clinically relevant non-tumor tissues from NF1 patients.29,36,43 In our study, p-ERK was measurable in all tissues from both WT and NF1 minipig untreated controls.